27 Jan FDA Approval of Spravato: A Breakthrough for Patients
The FDA approval of Spravato is a breakthrough for treatment-resistant depression, offering patients rapid relief. The U.S. Food and Drug Administration (FDA) has officially approved Spravato (esketamine) nasal spray as a standalone treatment for adults with treatment-resistant depression (TRD). This groundbreaking decision marks a new chapter in...